Effectiveness of rotavirus vaccination in Spain

Martinón-Torres, Federico; Alejandro, Marta Bouzón; Redondo-Collazo, Lorenzo; Lastres, Juan Manuel Sánchez; Díaz, Sonia Pértega; Pillado, Ma Teresa Seoane; Sánchez, José María Martinón

doi:10.4161/hv.7.7.15576

Cited by 63 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several countries in the EU (Belgium,18 Germany,19 France,25 Austria20 and Spain26) have reported a positive impact following the introduction of RV vaccination in their national immunisation programmes. Although RV vaccination in Greece is available through the national immunisation programme13 it is still an optional vaccine and is recommended only for the high-risk groups.…”

Section: Discussionmentioning

confidence: 99%

Burden of rotavirus gastroenteritis in children <5 years of age in Greece: hospital-based prospective surveillance (2008–2010)

et al. 2013

View full text Add to dashboard Cite

Participants: Children aged <5 years who visited the emergency rooms (ERs) or hospitalised with acute GE or acquired acute GE 48 h after hospitalisation and with a confirmed RV-positive stool test were enrolled.Primary and secondary outcome measures: The occurrence of RVGE among all acute GE ER visits and hospitalisations and the occurrence of nosocomial RVGE are reported with 95% exact CI. Age-specific proportions of RVGE, seasonality and prevalence of RV genotypes were estimated. Incidence rates of nosocomial acute GE and RVGE are expressed in terms of 1000 children-years with 95% exact Poisson CI. Median duration of hospitalisation and prolongation of hospitalisation due to nosocomial RVGE were reported.Results: RVGE proportions were 10.7% (95% CI 5.5% to 18.3%) and 23.8% (95% CI 20.0% to 28.0%) of acute GE ER visits and hospitalisations, respectively; and 21.6% (95% CI 9.8% to 38.2%) of nosocomial acute GE cases. The majority of RVGE cases occurred in children aged <24 months (53%). RV infection peaked between December and May (31.4%). The most common RV genotypes were G4 (59.6%) and P [8] (75.2%). The median duration of RVGE hospitalisation was 4 days (range 1-10 days). Incidence of nosocomial RVGE was 0.3 (95% CI 0.2 to 0.7)/1000 children-years. The median prolongation of hospitalisation due to nosocomial RVGE was 5 days (range 4-7 days).

show abstract

Section: Discussionmentioning

confidence: 99%

Burden of rotavirus gastroenteritis in children <5 years of age in Greece: hospital-based prospective surveillance (2008–2010)

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Fecal specimens were collected through active surveillance conducted at 3 New Vaccine Surveillance Network sites in the United States (Rochester, NY; Cincinnati, OH; Nashville, TN) year-round during October 2008–October 2009, as described ( 18 ). In brief, children visiting 1 of the 3 sites who were <5 years of age and had AGE (diarrhea [ > 3 loose stools in 24 hours] and/or vomiting [ > 1 episode in 24 hours]) for < 10 days and who lived in 1 of the 3 study areas were enrolled, and a fecal specimen was collected.…”

Section: Methodsmentioning

confidence: 99%

Comparison of 2 Assays for Diagnosing Rotavirus and Evaluating Vaccine Effectiveness in Children with Gastroenteritis

Tate¹,

Mijatovic-Rustempasic²,

Tam³

et al. 2013

Emerg. Infect. Dis.

View full text Add to dashboard Cite

We compared rotavirus detection rates in children with acute gastroenteritis (AGE) and in healthy controls using enzyme immunoassays (EIAs) and semiquantitative real-time reverse transcription PCR (qRT-PCR). We calculated rotavirus vaccine effectiveness using different laboratory-based case definitions to determine which best identified the proportion of disease that was vaccine preventable. Of 648 AGE patients, 158 (24%) were EIA positive, and 157 were also qRT-PCR positive. An additional 65 (10%) were qRT-PCR positive but EIA negative. Of 500 healthy controls, 1 was EIA positive and 24 (5%) were qRT-PCR positive. Rotavirus vaccine was highly effective (84% [95% CI 71%–91%]) in EIA-positive children but offered no significant protection (14% [95% CI −105% to 64%]) in EIA-negative children for whom virus was detected by qRT-PCR alone. Children with rotavirus detected by qRT-PCR but not by EIA were not protected by vaccination, suggesting that rotavirus detected by qRT-PCR alone might not be causally associated with AGE in all patients.

show abstract

“…Систематический обзор наблюдательных исследова-ний эффективности вакцинации против РВИ в Европе [6] обнаружил 9 исследований, в которых анализировалась эффективность вакцинации против РВИ (с примене-нием как 5-валентной, так и одновалентной вакцины) в отношении частоты госпитализации вакцинированных детей по поводу РВИ [7][8][9][10][11][12][13][14][15]. В соответствии с их резуль-татами, средняя величина эффекта при полном курсе вакцинации варьирует в пределах 80-98,3% [6].…”

Section: One Of the Main Causes Of The Incidence Of Intestinal Infectunclassified

Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

Рудакова¹,

Харит²,

Podkolzin³

et al. 2017

Pediatr. farmakol.

View full text Add to dashboard Cite

Effectiveness of rotavirus vaccination in Spain

Cited by 63 publications

References 12 publications

Burden of rotavirus gastroenteritis in children <5 years of age in Greece: hospital-based prospective surveillance (2008–2010)

Burden of rotavirus gastroenteritis in children <5 years of age in Greece: hospital-based prospective surveillance (2008–2010)

Comparison of 2 Assays for Diagnosing Rotavirus and Evaluating Vaccine Effectiveness in Children with Gastroenteritis

Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

Contact Info

Product

Resources

About